Roche has acquired Inflazome, an Irish biotech developing orally available NLRP3 inflammasome inhibitors to address clinical unmet needs across a wide variety of inflammatory diseases
The deal sees Inflazome’s shareholders receive an upfront payment of €380 million ($449m) and are eligible to receive additional contingent payments to be made based on the achievement of certain predetermined milestones.
The acquisition gives Roche full rights to Inflazome’s entire portfolio which is composed of clinical and preclinical orally available small molecule NLRP3 inhibitors.
Roche intends to further develop NLRP3 inhibitors across a wide variety of indications with high unmet medical need.
“With Inflazome now part of the Roche organization, Inflazome’s pioneering molecules are well positioned to be developed quickly and effectively so they can help patients suffering from debilitating diseases,” said Matt Cooper, CEO of Inflazome.